

Topics of today

- What's new in HBV
- How to control HBV in high endemic countries
- Imagery in liver diseases
- Vascular liver diseases
- End-stage liver disease
- Liver transplantation
- HCC

What's new in HBV

1st Session

- **Who and when to treat? Georgios Papatheodoridis**
EASL guidelines 2017
- **Is there a role for interferon? Pietro Lampertico**
PEG IFN+NUC
- **Long term safety and efficacy of NUCs. Maria Buti**
10 years TDF

What's new in HBV

Controversy

To stop or not to stop NUCs?

Thomas Berg and Adrian Gadano

What's new in HBV

How to control HBV in high endemic regions

Asia Jidong Jia

Africa Lamine Diouf

What's new in HBV

2nd Session

- **New anti-HBV therapies. Raymond Schinazi**
Future targets and combinations
- **HDV co-infection. Mario Rizzetto**
Delta hepatitis revisited
- **Access to therapy. Fabien Zoulim**
The next challenge

Two state of the art lectures

- The revolution of imagery in liver diseases:
current management and new concepts

Valérie Vilgrain

- Vascular liver diseases:

Dominique Valla

End-stage liver disease and transplantation

- **Infections complicating cirrhosis. Paolo Angeli**
Management in clinical practice
- **Allocation of liver grafts. Pierre-Alain Clavien**
What is the best system?
- **Long term outcome after LT. François Durand**
How to improve?

HCC

- HCC EASL guidelines 2018. Peter Galle
Inpress
- Impact of DAAs on HCC occurrence. Didier Samuel
What is the best system?
- New approaches in therapy. Bruno Sangro
New promising drugs and strategies

Take home messages

Michael Fried